2Crofford LJ,Lipsky PE,Brooks P,et al.Basic biology and clinical application of specific cyclooxygenas-2 inhibitors.Arthritis Rheum,2000,43:4-13.
3AMERICAN COLLEGE of RHEUMATOLOHY AD HOC GROUP on USE of SELECTIVE and NONSELECTIVE NONSTEROIDAL.Antiinflammatory drugs.Recommendations for use of selective and nonselective nonster-oidal anti-inflammatory drugs:an American College of Rheumatology White Paper.Arthritis Rheum,2008,59:1058-1073.
4Stichtenoth DO.Frolich J.The second generation of COX-2 inhibitors:what advantages do the newest offer.Drugs,2003.63:33-45.
5Juni P,Rutjes AW,Dieppe PA.Are selective COX-2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs.BMJ,2002,324:1287-1288.
6Bresalier RS,Sandler RS,Quan H,et al.Cardivascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.N Engl J Med,2005,352:1092-1102.
7Solomon SD,McMurray JJV,Pfeffer MA,et al.Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.N Engl J Med,2005,352:1071-1080.
8McGettigan P,Henry D.Cardiovascular risk and inhibition of cyclooxygenase:a systemic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.JAMA,2006,296:1633-1644.
9Juni P,Dieppe P.Older people should not be prescribed‘coxibs'in place of conventional NSAIDs.Age Ageing,2004,33:100-104.
10Ahmad SR,Kortepeter C,Brinker A,et al.Renal failure associated with the use of celecoxib and rofecoxib.Drug Safety,2002,25:537-544.
